Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy

Ramon Barajas, Soonmee Cha

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Glioma are the most common supra-tentorial brain tumor in the USA with an estimated annual incidence of 17,000 new cases per year. Dynamic susceptibility-weighted contrast-enhanced (DSC) perfusion MRI noninvasively characterizes tumor biology allowing for the diagnosis and therapeutic monitoring of glioma. This MRI technique utilizes the rapid changes in signal intensity caused by a rapid intravascular bolus of paramagnetic contrast agent to calculate physiologic perfusion metrics. DSC perfusion MRI has increasingly become an integrated part of glioma imaging. The specific aim of this article is to review the benefits of DSC perfusion MRI in the therapy of glioma.

Original languageEnglish (US)
Pages (from-to)407-419
Number of pages13
JournalCNS oncology
Volume3
Issue number6
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Keywords

  • cerebral blood volume
  • dynamic susceptibility-weighted contrast-enhanced perfusion MRI
  • glioblastoma
  • glioma
  • imaging genomics
  • metastasis
  • molecular imaging
  • peak height
  • percentage of signal intensity recovery

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy'. Together they form a unique fingerprint.

  • Cite this